As COVID-19 Cases rise among children Pfizer and Moderna’s vaccine’s get off to a slower start then expected in their adolescent trials leaving room for a potential sleeping giant to arise

Take a look at Avalon GloboCare (NASDAQ:AVCO)

36

As stated in the CNBC article “Pfizer says its Covid vaccine trial for kids ages 12 to 15 is fully enrolled” 

Pfizer (NYSE:PFE) said it had fully enrolled its Covid-19 vaccine trial in kids ages 12 to 15, a key step before the vaccine could be used in that age group.The study, an extension of the one used to support the company’s Emergency Use Authorization of the vaccine in people 16 and older, has enrolled 2,259 kids between 12 and 15, Pfizer told CNBC Friday. Its entry on a government website for clinical trials was updated to note it’s no longer recruiting subjects. The vaccine, developed with German partner BioNTech,(NASDAQ:BNTX) was authorized for people ages 16 and older in December. Trials in younger age groups are necessary to ensure the correct dose, as well as safety and efficacy in those different groups, said Dr. Evan Anderson, a pediatrician at Emory University School of Medicine.

While children are less affected by Covid-19 than adults, they do still catch the virus and get sick. Some have even died. More than 2.5 million cases of Covid-19 had been reported in children as of Jan. 14, about 13% of all cases, according to a report from the American Academy of Pediatrics and the Children’s Hospital Association.

Pfizer(NYSE: PFE) declined to say when it expected results from the trial, which are dependent on the rate of infections observed to be able to compare the rates in the placebo group to those receiving the vaccine. With higher infection rates across the U.S. since the fall — the seven-day average of daily cases is now about 187,500, according to a CNBC analysis of Johns Hopkins University data — vaccine efficacy trials have seen their readouts sped up.But recruitment for trials in adolescents had been slower than hoped, at least for Moderna’s (NASDAQ:MRNA) study in kids age 12 to 17, said Moncef Slaoui, chief adviser to Operation Warp Speed, the Trump Administration’s vaccines effort, at its last briefing Jan. 12.

As big pharma races to save millions of lives there is a smaller less known “sleeping giant” in the CAR-T space developing advanced S-layer technology with limitless applications in the key development of an intranasal vaccine.  S-Layer  “surface layer” technology is used to develop an intranasal vaccine that attaches to the mucosal membrane CEO Dr. David Jin pointed out. “We see our vaccine candidate as a complement to any injectable vaccines in clinical trials, because it could provide first-line immune protection at the virus’s entrance site”. Adding a coat of an S-layer onto solid surfaces can greatly improve the function of a therapeutic, vaccine, or device. The S-layer allows enhanced efficiency and interaction of targeted proteins and molecules for better function.

Avalon GloboCare (NASDAQ:AVCO) is in the process of establishing a state-of-the-art research facility, the Christian Doppler Laboratory, located on the BOKU campus in Vienna, Austria, under the scientific leadership of Professor Eva-Kathrin Ehmoser, the Head of BOKU’s Institute for Synthetic Bioarchitectures and Professor Uwe Sleytr, a member of the Austrian Academy of Sciences. In connection with the new facility, Avalon and BOKU have signed a Memorandum of Understanding (MOU) to jointly apply for a matching research grant from the prestigious Christian Doppler Laboratory Foundation. Avalon also has research being done in MIT (Massachusetts Institute of Technology), the UNRLS (University of Natural Resources and life sciences in Australia), Weill Cornell Medicine in New York City and the Lu Daopei Medical Group in China, which has the country’s top ranked hematology and bone marrow transplant program 

In the December 2020 issue of Nature’s Biopharma Dealmakers, Avalon’s President and CEO, David Jin, M.D., Ph.D., highlighted Avalon’s ongoing scientific and clinical developments including a first-in-human trial of a mucosal, intranasal vaccine against SARS-CoV-2 that is planned for early 2021. Dr. Jin also described the company’s innovative, allogeneic mesenchymal stromal cell (MSC) therapy candidate, CB-MSC-1, which possess unique anti-inflammatory and immunomodulatory activities, as well as AVA-001, Avalon’s third-generation CAR T cell therapy that has shown robust activity in patients with relapsed, refractory B cell acute lymphoblastic leukemia in a Phase 1 trial (Avalon feature in Biopharma Dealmakers).

“We are excited and motivated to join forces with the researchers at BOKU to drive innovation. We have already begun a collaboration on the mucosal SARS-CoV-2 vaccine and are moving quickly to establish additional joint research endeavors to bring about innovative technologies and new medicines to patients,” said Dr. Jin.Avalon GloboCare, is a young, $100 million market cap company that has arguably some of the brightest minds in cell-based technology who have a competitive advantage with their “S-Layer” technology in a vaccine market that is expected to grow to approximately 93.billion by 2026 according to Forbes business . This small cap biotechnology company is working towards the goal of changing the way we fight the devastating affects of diseases that relentlessly attack our immune systems by using our own bodies against us. In the first quarter of 2020, Avalon GloboCare successfully completed a phase 1 first-in-human clinical study of AVA-001 in China for the treatment of relapsed refractory B cell acute lymphoblastic leukemia (R/R B-ALL). 90% of R/R B-ALL patients achieved complete remission with one dose and within one month of treatment, and then proceeded to a curative-intent allogeneic bone marrow transplant.  With more upcoming catalysts in early 2021, it is safe to say that there is a large potential upside in AVCO’s stock that currently rose from 1.14 to 1.21, as the market is anticipating updates on their progress on multiple clinical trials, leaving the question most investors are asking themselves.” When will Avalon GloboCare (NASDAQ:AVCO) take off ?” 

About EmergingGrowth.com

Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated two thousand five hundred dollars in consideration for its work with Avalon GloboCare Corp. through the date this was published. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here, https://emerginggrowth.com/6282-723726/  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.